Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma

Jesus G. Berdeja; Jacob P. Laubach; Joshua Richter; Steve Stricker; Andrew Spencer; Paul G. Richardson; Ajai Chari

doi:10.1016/j.clml.2021.06.020

Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma

Jesus G. Berdeja, Jacob P. Laubach, Joshua Richter, Steve Stricker, Andrew Spencer, Paul G. Richardson, Ajai Chari

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

Relapsed and refractory multiple myeloma (RRMM) presents a therapeutic challenge due to the development of drug resistance. Panobinostat is an oral histone deacetylase inhibitor (HDACi) that affects multiple cellular pathways and has demonstrated the ability to resensitize refractory-multiple myeloma cells in preclinical studies, as well as in patients with RRMM in clinical trials. Synergy of panobinostat with a number of different classes of antimyeloma drugs (proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies) has also been shown. Panobinostat is a promising HDACi for the treatment of multiple myeloma. Here, we present a comprehensive review of preclinical and clinical studies of panobinostat.

Original language	English
Pages (from-to)	752-765
Number of pages	14
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	21
Issue number	11
DOIs	https://doi.org/10.1016/j.clml.2021.06.020
State	Published - Nov 2021

Keywords

Histone deacetylase inhibitors
Refractory
Relapsed

Access to Document

10.1016/j.clml.2021.06.020

Cite this

@article{9e8006242a0544f88bc60f8948850fe9,

title = "Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma",

abstract = "Relapsed and refractory multiple myeloma (RRMM) presents a therapeutic challenge due to the development of drug resistance. Panobinostat is an oral histone deacetylase inhibitor (HDACi) that affects multiple cellular pathways and has demonstrated the ability to resensitize refractory-multiple myeloma cells in preclinical studies, as well as in patients with RRMM in clinical trials. Synergy of panobinostat with a number of different classes of antimyeloma drugs (proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies) has also been shown. Panobinostat is a promising HDACi for the treatment of multiple myeloma. Here, we present a comprehensive review of preclinical and clinical studies of panobinostat.",

keywords = "Histone deacetylase inhibitors, Refractory, Relapsed",

author = "Berdeja, {Jesus G.} and Laubach, {Jacob P.} and Joshua Richter and Steve Stricker and Andrew Spencer and Richardson, {Paul G.} and Ajai Chari",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = nov,

doi = "10.1016/j.clml.2021.06.020",

language = "English",

volume = "21",

pages = "752--765",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Elsevier Inc.",

number = "11",

}

TY - JOUR

T1 - Panobinostat From Bench to Bedside

T2 - Rethinking the Treatment Paradigm for Multiple Myeloma

AU - Berdeja, Jesus G.

AU - Laubach, Jacob P.

AU - Richter, Joshua

AU - Stricker, Steve

AU - Spencer, Andrew

AU - Richardson, Paul G.

AU - Chari, Ajai

PY - 2021/11

Y1 - 2021/11

N2 - Relapsed and refractory multiple myeloma (RRMM) presents a therapeutic challenge due to the development of drug resistance. Panobinostat is an oral histone deacetylase inhibitor (HDACi) that affects multiple cellular pathways and has demonstrated the ability to resensitize refractory-multiple myeloma cells in preclinical studies, as well as in patients with RRMM in clinical trials. Synergy of panobinostat with a number of different classes of antimyeloma drugs (proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies) has also been shown. Panobinostat is a promising HDACi for the treatment of multiple myeloma. Here, we present a comprehensive review of preclinical and clinical studies of panobinostat.

AB - Relapsed and refractory multiple myeloma (RRMM) presents a therapeutic challenge due to the development of drug resistance. Panobinostat is an oral histone deacetylase inhibitor (HDACi) that affects multiple cellular pathways and has demonstrated the ability to resensitize refractory-multiple myeloma cells in preclinical studies, as well as in patients with RRMM in clinical trials. Synergy of panobinostat with a number of different classes of antimyeloma drugs (proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies) has also been shown. Panobinostat is a promising HDACi for the treatment of multiple myeloma. Here, we present a comprehensive review of preclinical and clinical studies of panobinostat.

KW - Histone deacetylase inhibitors

KW - Refractory

KW - Relapsed

UR - http://www.scopus.com/inward/record.url?scp=85111577138&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2021.06.020

DO - 10.1016/j.clml.2021.06.020

M3 - Review article

C2 - 34340951

AN - SCOPUS:85111577138

SN - 2152-2650

VL - 21

SP - 752

EP - 765

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 11

ER -

Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma

Abstract

Keywords

Access to Document

Fingerprint

Cite this